Standard of Care sensibility: Rituximab = yes (30mg/kg).
SUDHL-4 cells
Human SUDHL-4 cells were isolated from the peritoneal effusion of a patient with a DLBCL
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.
The mice bearing SUDHL-4 tumours can be treated by intra-peritoneal, intra-venous, intratumoral or subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the SUDHL-4 cells as xenograft Mean ± SEM (n=8; take rate 87.5%)
Antineo can also perform an intra-medullar implantation